Literature DB >> 27047958

Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer.

Theodoros Karantanos1, Styliani Karanika1.   

Abstract

Entities:  

Year:  2016        PMID： 27047958      PMCID： PMC4791328          DOI： 10.21037/atm.2016.01.23

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  7 in total

Review 1.  The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer.

Authors:  Roberto Iacovelli; Elena Verri; Maria Cossu Rocca; Gaetano Aurilio; Daniela Cullurà; Ottavio De Cobelli; Franco Nolè
Journal:  Eur J Cancer       Date:  2015-07-10       Impact factor: 9.162

Review 2.  Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.

Authors:  Åsa Tivesten; Jehonathan H Pinthus; Noel Clarke; Wilhelmina Duivenvoorden; Jan Nilsson
Journal:  Urol Oncol       Date:  2015-06-30       Impact factor: 3.498

3.  Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

Authors:  Sean O'Farrell; Hans Garmo; Lars Holmberg; Jan Adolfsson; Pär Stattin; Mieke Van Hemelrijck
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

4.  Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.

Authors:  Peter C Albertsen; Laurence Klotz; Bertrand Tombal; James Grady; Tine K Olesen; Jan Nilsson
Journal:  Eur Urol       Date:  2013-11-01       Impact factor: 20.096

5.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Authors:  Frances Dockery; Christopher J Bulpitt; Sanjiv Agarwal; Mandy Donaldson; Chakravarthi Rajkumar
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

Review 6.  [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].

Authors:  Axel S Merseburger; Daniel Sedding; Kai Hüter
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

Review 7.  Testosterone and cardioprotection against myocardial ischemia.

Authors:  Sharon Tsang; Jing Liu; Tak Ming Wong
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2007-06
  7 in total
  1 in total

Review 1.  Androgen deprivation therapy and side effects: are GnRH antagonists safer?

Authors:  Stephen J Freedland; Per-Anders Abrahamsson
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.